The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Targeting deadly drug-resistant acinetobacter infections
Industry body aims to strengthen policy advocacy, innovation, and global competitiveness of India's fast-growing CRDMO sector
Dr. Jain brings extensive experience in the biotech and pharma sectors and has been instrumental in driving innovation, vaccine development, and healthcare advancement
Veteran healthcare leader to oversee operations across Tamil Nadu and Kerala, driving growth and operational excellence
Chennai based Bioneemtec India has received support from Technology Development Board for commercializing indigenous green chemistry technologies to produce critical pharmaceutical ingredients
The move signals a major expansion in access to next-generation weight-loss therapies
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Subscribe To Our Newsletter & Stay Updated
